Drug intelligence / Profile preview

soluble siglec-9

Development stage
Preclinical
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous, Intraperitoneal
01

Overview

Soluble siglec-9 is a recombinant, soluble form of the human sialic acid-binding immunoglobulin-like lectin 9 (Siglec-9), an immunoregulatory protein of the Ig superfamily. As a decoy receptor, soluble siglec-9 binds to sialic acid–containing ligands and modulates immune function by antagonizing endogenous, cell-bound siglec-9 signaling. Preclinical studies show that this protein can inhibit pro-inflammatory responses in models of inflammatory bowel disease and rheumatoid arthritis, primarily by suppressing the activation of nuclear factor kappa B (NF-κB) in immune and epithelial cells, reducing cytokines such as TNF-α and IL-8, and rebalancing regulatory and effector T cell subsets. Soluble siglec-9 acts as an immune checkpoint modulator and is being investigated as a potential therapeutic agent in autoimmune and inflammatory diseases.

Other names
sSiglec-9sSiglec9sSiglec 9soluble sialic acid-binding immunoglobulin-like lectin 9recombinant soluble siglec-9
02

Targets

sLeX (Sialyl-Lewis X antigen)NF-κBSIGLEC9 (Sialic acid-binding immunoglobulin-like lectin 9)

Beyond the preview

Go deeper on soluble siglec-9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on soluble siglec-9.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call